Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Pharmacokinetic drug interactions with oral contraceptives.Clinical Pharmacokinetics. 1990; 8: 472-484
Evelyn, B., Toigo, T., Banks, D., Pohl, D., Gray, K., Robins, B., et al. (2001). Women's participation in clinical trials and a gender-related labeling: A review of New molecular entities approved 1995–1999. Available: http://www.fda.gov/cder/reports/womens_health/women_clin_trials.htm. Accessed February 29, 2008.
- General considerations for the clinical evaluation of drugs.(HEW Publication No. (FDA) 77-3040. Available:)Accessed February 29, 2008)
Food and Drug Administration (FDA). (1993). Study and evaluation of gender differences in the clinical evaluation of drugs. Available: http://www.fda.gov/cder/guidance/old036fn.pdf. Accessed February 29, 2008.
Food and Drug Administration (FDA). (1998). Center for Drug Evaluation and Research. The CDER Handbook. Available: http://www.fda.gov/cder/handbook/phase1.htm. Accessed February 29, 2008.
Food and Drug Administration (FDA). (2004). Manual of policies and procedures. Thalidomide as a teratogen. Center for Drug Evaluation and Research MaPP 6010.3. Available: http://www.fda.gov/cder/mapp/6010.3.pdf. Accessed February 29, 2008.
Government Accountability Office (GAO). (1992). Women's health: FDA needs to ensure more study of gender differences in prescription drug testing, HRD-93–17. Available: http://archive.gao.gov/d35t11/147861.pdf. Accessed February 29, 2008.
Government Accountability Office (GAO). (2001a). Drugs withdrawn from market. Drug safety: Most drugs withdrawn in recent years had greater health risks for women. GAO-01-286R, 2001. Available: http://www.gao.gov/new.items/d01286r.pdf. Accessed February 29, 2008.
Government Accountability Office (GAO). (2001b). Women's health: Women sufficiently represented in new drug testing, but FDA oversight needs improvement. Available: at http://www.gao.gov/new.items/d01754.pdf. Accessed February 29, 2008.
Government Accountability Office (GAO). (2006). New drug development: Science, business, regulatory, and intellectual property issues cited as hampering drug development efforts. Available: http://www.gao.gov/new.items/d0749.pdf. Accessed February 29, 2008.
- Thalidomide as a teratogen.in: Gilbert S.F. Developmental biology. Elsevier, Sunderland, MA2006: 667-675
- Gender effects in pharmacokinetics and pharmacodynamics.Drugs. 1995; 50: 222-239
- Gender-based differences in the toxicity of pharmaceuticals—The Food and Drug Administration's perspective.International Journal of Toxicology. 2001; 20: 149
- Do women have more adverse drug reactions?.American Journal of Clinical Dermatology. 2001; 2: 349-351
- Women in clinical trials: An FDA perspective.Science. 1995; 269: 793
- Influence of gender on the pharmacokinetics and pharmacodynamics of drugs.International Journal of Clinical Pharmacology and Therapeutics. 1998; 36: 586-590
- Wizemann T.M. Pardue M.-L. Exploring the biological contributions to human health: Does sex matter? National Academy Press, Washington, DC2001: 117-172
Yang, Y., Carlin, A., Faustino, P., Pagán-Motta, P., Hamad, M., He, R., et al. (n.d. In press). Participation of women in clinical trials for new drugs approved by the Food and Drug Administration between 2000–2002. Unpublished data accepted for publication in the Journal of women's health.